Tamiflu News and Research

RSS
FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

Cancer drug may help combat flu

Cancer drug may help combat flu

Natco Pharma files ANDA with FDA for generic version of Tamiflu

Natco Pharma files ANDA with FDA for generic version of Tamiflu

Natco Pharma submits ANDA to FDA for generic version of Tamiflu 75 mg capsules

Natco Pharma submits ANDA to FDA for generic version of Tamiflu 75 mg capsules

Study highlights importance of independent evaluation of Tamiflu drug

Study highlights importance of independent evaluation of Tamiflu drug

Air purifier helps reduce H1N1 swine flu virus on contact

Air purifier helps reduce H1N1 swine flu virus on contact

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Lung transplant saves economist from near-lethal bout of swine flu

Lung transplant saves economist from near-lethal bout of swine flu

More effective treatment for severe form of influenza

More effective treatment for severe form of influenza

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Flu deaths analyzed for future lessons

Flu deaths analyzed for future lessons

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

News outlets look at how H1N1 will inform WHO's future outbreak response

News outlets look at how H1N1 will inform WHO's future outbreak response

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

New development in flu prevention & treatment

New development in flu prevention & treatment